Evidence map›Paper›PMID 21694939›Full record

ArticleInternational journal of nephrology and renovascular disease2010

Update on the diagnosis and management of acute kidney injury.

Ali Akcay, Kultigin Turkmen, DongWon Lee, Charles L Edelstein

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in International journal of nephrology and renovascular disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02530359 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2015 to 2016Enrolled90ConditionsAcute Kidney Injury, SepsisArmsPirfenidone extended release, Placebo equivalent
NCT05297214 unknown statusnot on this mapstarted 2022, after this paper: background citation

A Study of Acute Kidney Injury in Children at Sohag University Hospital

TypeobservationalSponsorSohag UniversityRan2022 to 2022Enrolled50ConditionsAcute Kidney InjuryArmsserum creatinine and Other investigations will be done according to the case
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. The protective impacts ofToxicology research · 2022
    Article
  7. Article
  8. Article
  9. Journal of parasitology research · 2021
    Article
  10. Article
  11. Ginsenoside Rh1 Alleviates HK-2 Apoptosis by Inhibiting ROS and the JNK/p53 Pathways.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  12. Acute and Subacute Toxicity Profiles of the Methanol Extract ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Risk factors and prognostic factors of acute kidney injury in children: A retrospective study between 2003 and 2013.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali AkcayDivision of Renal Diseases and Hypertension, University of Colorado and the Health Sciences Center, Aurora, Colorado, USA.
Kultigin Turkmen
DongWon Lee
Charles L Edelstein

Funding

ROLE OF CASPASES IN ISCHEMIC ACUTE RENAL FAILURER01DK056851 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EDELSTEIN, CHARLES LOUIS · 2001 to 2010
$2.5M
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)R01DK074835 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EDELSTEIN, CHARLES LOUIS · 2007 to 2011
$1.8M
NIDDK NIH HHS R01 DK056851NIDDK NIH HHS R01 DK074835
6 · The paper itself

Abstract

Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality. This review provides essential information for the diagnosis and management of AKI. Blood urea nitrogen and serum creatinine are used for the diagnosis of AKI. The review also focuses on recent studies on the diagnosis of AKI using the RIFLE (R-renal risk, I-injury, F-failure, L-loss of kidney function, E-end stage kidney disease) and Acute Kidney Injury Network criteria, and serum and urine AKI biomarkers. Dialysis is the only Food and Drug Administration-approved therapy for AKI. Recent studies on the dose of dialysis in AKI are reviewed.

Indexed as

acute kidney injurybiomarkersinterleukin-18

Identifiers

PMID21694939
PMCPMC3108768
OpenAlexW1980855945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.